Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: The experience of an outpatient dermatological clinic for psoriasis

Clinical and Experimental Dermatology

Volumn 40, Issue 2, 2015, Pages 136-141

  Graceffa, D ^a   Maiani, E ^a   Sperduti, I ^a   Ceralli, F ^b   Bonifati, Claudio ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; ETRETIN; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; USTEKINUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; COHORT ANALYSIS; DACTYLITIS; DRUG EFFICACY; ENTHESITIS; FEMALE; FIBROMYALGIA; HEALTH CENTER; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; PROCEDURES;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL FACTORS; BIOLOGICAL THERAPY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923214005     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12504     Document Type: Article

References (24)

1. Gisondi P, Girolomoni G, Sampogna F et al. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005; 15: 279-83.
2. Lloyd P, Ryan C, Menter A. Psoriatic arthritis: an update. Arthritis 2012; 2012: 176298.
3. McInners IS, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo controlled PSUMMIT 1 trial. Lancet 2013; 382: 780-9.
4. de Vlam K, Lories RJU. Remission in psoriatic arthritis. Curr Rheumatol Rep 2008; 10: 297-302.
5. Cantini F, Niccoli L, Nannini C et al. Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs. J Rheumatol 2009; 36 (Suppl.): 78-80.
6. Saber TP, Ng CT, Renard G et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010; 12: 2-6.
7. de Vlam K, Lories RJU. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology 2006; 45: 321-4.
8. Atteno M, Peluso R, Costa L et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 2010; 29: 399-403.
9. Saber TP, Fearon U, Veale DJ. Is remission a more realistic goal in psoriatic arthritis? Ther Adv Musculoskel Dis 2011; 3: 3-7.
10. WHO. Obesity and overweight. Fact sheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed 8 June 2014).
11. Bonifati C, Elia F, Francesconi F et al. The diagnosis of early psoriatic arthritis in an outpatient dermatological centre for psoriasis. J Eur Acad Dermatol Venereol 2012; 26: 213-20.
12. Taylor W, Gladman D, Helliwell P et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
13. Gladman D, Farewell V, Buskila D et al. Reliability of measurements of active and damaged joints in psoriatic arthritis. J Rheumatol 1990; 17: 62-4.
14. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
15. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008; 59: 686-91.
16. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
17. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
18. Wolfe F, Smythe HA, Yunus MB et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria Committee. Arthritis Rheum 1990; 33: 160-72.
19. Eder L, Chandran V, Schentag CT et al. Time and predictors of response to tumour necrosis factor-a blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology 2010; 49: 1361-6.
20. Coates LC, Cook R, Lee K et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res 2010; 62: 970-6.
21. Thune PO. The prevalence of fibromyalgia among patients with psoriasis. Acta Derm Venereol 2005; 85: 33-7.
22. Magrey NM, Antonelli M, James N, Khan MS. High frequency of fibromyalgia in patients with psoriatic arthritis: a pilot study. Arthritis 2013; 2013: 762921.
23. Konno T. Differentiation of the clinical features of psoriatic arthritis and fibromyalgia. J Rheumatol 2012; 39: 2221; author reply 2222.
24. Gladman DD. Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis. Nat Clin Pract Rheumatol 2008; 4: 510-11.